TIDMORPH

Open Orphan PLC

10 February 2020

10 February 2020

RNS REACH

Open Orphan Plc

("Open Orphan" or the "Company")

Value the Markets Webinar

Tuesday, 11 February 2020 at 7 pm

Open Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce that the Company will be hosting a webinar for investors at 7pm on Tuesday 11(th) February. For those wishing to join the event the participant details are below.

Join via Website: https://vtm.clickmeeting.com/orph

Join via Phone: +44 (20) 7048-4146

When prompted please provide the Participant's PIN code 159543# followed by the # key

For further information please contact

 
 
                                                +353 (0)1 644 
 Open Orphan plc                                0007 
  Cathal Friel, Executive Chairman              +44 (0)20 7347 
  Trevor Phillips, Chief Executive Officer      5350 
 
 Arden Partners plc (Nominated Adviser and 
  Joint Broker)                               +44 (0)20 7614 
  John Llewellyn-Lloyd / Benjamin Cryer        5900 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                     +353 (0)1 679 
  Anthony Farrell                              6363 
 
 Camarco (Financial PR) 
                                              +44 (0)20 3757 
 Tom Huddart / Daniel Sherwen                  4980

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

Notes to Editors:

Open Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provision of viral challenge studies, vaccine and viral laboratory services, supporting product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness of the Coronavirus in 2020. The Merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRATMMBTMTBBBIM

(END) Dow Jones Newswires

February 10, 2020 06:17 ET (11:17 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Hvivo Charts.
Hvivo (LSE:HVO)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Hvivo Charts.